ML20137J211

Supports Use of ACMUI & Professional Medical Organizations & Societies That Was Proposed in Commission'S Preliminary Views Re DSI-7, Matls/Medical Oversight

ML20137J211
Person / Time
Issue date:	02/21/1997
From:	Rogers K NRC COMMISSION (OCM)
To:	Diaz N, Dicus G, Shirley Ann Jackson, Mcgaffigan E, The Chairman NRC COMMISSION (OCM)
Shared Package
ML20137J180	List: ML20137J177 ML20137J183 ML20137J197 ML20137J211 ML20137J229 ML20137J234 ML20137J249 ML20137J257
References
COMSECY-96-057, COMSECY-96-57, DSI-7, SECY-96-057-C, SECY-96-57-C, NUDOCS 9704030244
Download: ML20137J211 (1)

Text

. - - - - -. -- - - .-- . - . - - - - - --_- --

l

• • • • • • '*******eeoeoea,,,

/>RRECy 'o UNITED STATES l

!' y

5. "g NUCLEAR REGULATORY COMMISSION W ASHINGTON, D.C. 20555

• REl_ EASED TO THE PDR 1 ;e b-l cats kkingja!3

....+

OFFICE OF THE cOuuissioNEn January 21,1997 i

4 MEMORANDUM TO: Chairman Jackson

! Commissioner Dieus

Commissioner Diaz l Commissioner McGaffigan 1

FROM: Commissioner Rogers Q, l

i i

SUBJECT:

COMSECY-g6 057: MATERIALS / MEDICAL OVERSIGHT - DSI-7 After a review of the Phase ll Stakeholder interschon Report and after listening to the Steering Committee briefing ori January 13, I beheve the Commission's preisminary views on this DSI .

l capture my position relative to NRC's regulabon of Atomic Energy Act (AEA) materials and, in l l

' particular, its program for medical use of those materials. More specifically, I still favor a l

l combination of Option 2 (Continue the ongoing program with improvements) and Ophon 3 (Decrease oversight of low-risk activities with continued emphasis of high-risk schvities). I also l

continue to support the use of ACMUI and professional medical organizations and societies that was proposed in the Commission's preliminary views.  ;

i

! I believe that the changes to 10 CFR Part 35 that would be needed to implement the l 1

Commission's views should be accornplished through an enhanced participatory process. This would allow a full exploration of views regarding the application of a risk-informed, performance-i based approach to NRC's oversight of medical activities. A significant number of commenters ,

favored an expansion of the scope of NRC regulation to include all medical use of rachation.

While i do not object to this issue being further considered in conjunchon with an enhanced

] participatory rulemaking process, I would not favor re-opening the AEA solely for the purpose of j such an expansion (however, if NRC were to be given broader oversight over OOE, the j '

authorizing legislation might be used as a vehicle).V'^-

i J

i i cc: EDO j OGC j SECY e

+

d 1

l 9704030244 970401

, PDR NRCSA I